| Entries |
| Document | Title | Date |
|---|
| 20080233078 | THERAPEUTIC POLYESTERS AND POLYAMIDES - Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided. | 09-25-2008 |
| 20080247988 | METHODS OF MAKING AND USING SURFACTANT POLYMERS - Comblike, surfactant polymers for changing the surface properties of biomaterials are provided. Such surfactant polymers comprise a polymeric backbone of repeating monomeric units having functional groups for coupling with side chains, a plurality of hydrophobic side chains linked to said backbone via the functional groups, and a plurality of hydrophilic side chains linked to said backbone via the functional groups. The hydrophobic side chains comprise an alkyl group comprising from 2 to 18 methylene groups. The alkyl groups are linked to the polymeric backbone through ester linkages, secondary amine linkages, or, preferably, amide linkages. The hydrophilic side chain is selected from the group consisting of: a neutral oligosaccharide, which, preferably, has weight average molecular weight of less than 7000; a charged oligosaccharide, preferably a negatively charged oligosaccharide having a weight average molecular weight of less than 10,000; an oligopeptide of from about 3 to about 30 amino acid residues, said oligopeptide having an amino acid sequence which interacts with protein receptors on the surface of cells; and combinations thereof. Methods of making the surfactant polymers and using the surfactant polymers to alter the surface properties of a biomaterial are also provided. | 10-09-2008 |
| 20080253986 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 10-16-2008 |
| 20080253987 | POLYMERIC TISSUE SEALANT - Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:
| 10-16-2008 |
| 20080267904 | Compositions Having A High Antiviral And Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain a phenolic antimicrobial agent, a surfactant, a hydrotrope, a hydric solvent, and an organic acid, wherein the phenolic antimicrobial agent is present in a continuous aqueous phase in an amount of at least 25% of saturation concentration and the composition has a pH of about 5 or less. | 10-30-2008 |
| 20080292579 | Polymer-Based Serum Albumin Substitute - This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers. | 11-27-2008 |
| 20080317704 | Control of ice-crystal growth by non-proteinaceous substance - The present invention makes it possible to attain various applications using antifreeze activity without an antifreeze protein. The agent for the inhibition of ice-crystal growth includes a non-proteinaceous substance, wherein an aqueous solution of the non-proteinaceous substance in a concentration of 10 mg/ml causes the deposition of non-flat disk-shaped ice crystals. The agent for the lowering of an ice-crystal growth initiation temperature includes a non-proteinaceous substance, wherein an aqueous solution of the non-proteinaceous substance in a concentration of 10 mg/ml shows thermal hysteresis by a temperature of 0.020° C. or higher. The agent for the control of water freezing includes a non-proteinaceous substance, wherein an aqueous solution of the non-proteinaceous substance in a concentration of 10 mg/ml shows thermal hysteresis by a temperature of 0.020° C. or higher and causes the deposition of non-flat disk-shaped ice crystals. The above non-proteinaceous substances are usually polymers each having a carbon chain as the main chain. | 12-25-2008 |
| 20090016986 | Cosmetic Composition, a Pharmaceutical Composition and a Process for Preparing Said Compositions - The present invention relates to a cosmetic composition and to a pharmaceutical composition that comprise several agents of topical use and optionally sunscreens. This composition comprises an aqueous medium containing at least one highly polar substance without, however, having the inconveniences noticed in similar compositions of the prior art. These compositions combine the benefits from water-soluble active with the properties of softness and texture that are typical of products that comprise oily-alcoholic, oily or oily-waxy base. Further, the present invention relates to a process for preparing said cosmetic composition and pharmaceutical composition. | 01-15-2009 |
| 20090047234 | Compositions for nasal delivery - The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery. | 02-19-2009 |
| 20090060860 | BETA-CYCLODEXTRINS AS NUCLEATING AGENTS FOR POLY(LACTIC ACID) - The use of β-CDs as nucleating agents for PLA to provide an increase in polymer crystallinity is described. The improvement in increased crystallinity is related to the percentage of β-CDs used. For the analyzed films, crystallinity was approximately 1.47% in the absence of a nucleating agent, and approximately 17.85% in the presence of the maximum amount of nucleating agent tested (e.g., 30%). Thus, improvement in processability, producability, and heat resistance of PLA will depend on the amount of β-CDs loaded. Additionally, loading PLA with β-CDs carrying an antifungal volatile is an effective way to increase PLA crystallinity besides avoiding fungal development when used in active packaging. In this case, the antifungal volatiles, along with changes in headspace concentration because of changes in crystallinity, may prolong the fresh produce shelf life. | 03-05-2009 |
| 20090130052 | Biocide, in particular an agent with fungicidal activity - The invention relates to a polymeric condensation product which can be obtained by reacting guanidine or its salt with an alkylene diamine and an oxyalkylene diamine. Said condensation product has biocidal, in particular fungicidal, activity and is usable as a plant protection product. | 05-21-2009 |
| 20090142293 | Polyammonium/Polysiloxane Copolymers - The invention relates to polyammonium/polysiloxane copolymers, methods for production and use thereof. | 06-04-2009 |
| 20090220449 | SUBSTITUTED ORGANOPOLYSILOXANES AND USES THEREOF - The invention relates to new compounds of Formula 1: [(O | 09-03-2009 |
| 20090226395 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential - The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues. | 09-10-2009 |
| 20090263347 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues. | 10-22-2009 |
| 20100028292 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof - Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided. | 02-04-2010 |
| 20100068171 | INJECTABLE BONE/POLYMER COMPOSITE BONE VOID FILLERS - A biodegradable polyurethane scaffold that includes a HDI trimer polyisocyanate and at least one polyol; wherein the density of said scaffold is from about 50 to about 250 kg m−3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore. The scaffolds of the present invention are injectable as polyurethane foams, and are useful in the field of tissue engineering. | 03-18-2010 |
| 20100080768 | Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin - The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents; (2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia; (3) it is a treatment of inflammatory conditions of mucosae; (4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin. | 04-01-2010 |
| 20100092422 | Poly ( -hydroxy short-medium chain fatty acid) - The present invention provides a composition comprising a polymer of a β-hydroxy short-medium chain fatty acid, which is used for delivering the β-hydroxy short-medium chain fatty acid or an oligomer thereof to the large intestine. In case the composition is administrated orally, the composition will be delivered to the large intestine, without being degraded in the stomach or short intestine, and degraded by the large intestinal bacterial flora and release the short-medium chain fatty acid or an oligomer thereof. The released short-medium chain fatty acid or an oligomer thereof has useful physiological activities and is effective for treating or preventing inflammatory diseases or cancer in the large intestine. | 04-15-2010 |
| 20100098655 | Aqueous Oligo- And Polyester Formulations - Aqueous formulations of soil release polyesters are claimed, which comprise from 50 to 90% by weight of soil release polyester and from 0.1 to 40% by weight of a phosphonic acid or of a phosphonate. The addition of the phosphonic acid or of the phosphonate allows the preparation of formulations of the soil release polyesters which are stable and have a low viscosity. | 04-22-2010 |
| 20100124542 | AMINE DENDRIMERS - Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia. | 05-20-2010 |
| 20100158852 | METHOD FOR REDUCTION OF MICROBES ON SURFACES - A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a polyalkyleneoxide polysiloxane surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations. | 06-24-2010 |
| 20100158853 | POLYALKYLENE OXIDE POLYQUATERNARY AMMONIUM BIOCIDES - Disclosed are polyquaternary ammonium polymers containing polyalkylene oxide groups according to formula (I) wherein [A] | 06-24-2010 |
| 20100158854 | METHOD FOR TREATMENT OF AIRWAY AND APPARATUS AND KIT FOR USE THEREWITH - A method of treating an airway in a mammalian body having a mouth, soft palate, uvula, throat and tongue. An implant-forming material is introduced into at least one of the soft palate and uvula for treating at least one of snoring and sleep apnea. An apparatus and kit are provided. | 06-24-2010 |
| 20100166696 | AMIDO-AMINE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers and compositions, including amide compounds and amide polymers, may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions. | 07-01-2010 |
| 20100226874 | BIOCIDAL COMPOSITIONS - Embodiments of the present subject matter provide a biocidal composition comprising an aqueous mixture of (a) a phosphonium compound and (b) a polymeric ammonium compound, wherein the weight ratio of compound (a) to compound (b) is from 0.2:1 to 20:1, and wherein
| 09-09-2010 |
| 20100266527 | ANTI-MICROBIAL POLYMERS AND THEIR COMPOSITIONS - Polymers derived directly from acrolein monomer that are substantially soluble in water and/or aqueous media, together with methods for preparing same and compositions containing such for use as an anti-microbial, anti-cancer, anti-inflammatory and/or anti-coagulant. | 10-21-2010 |
| 20100272673 | Ionomeric Silicone Thermoplastic Elastomers - This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled. | 10-28-2010 |
| 20100297058 | PREBIOTIC COMPOSITION - The present invention provides for use of a composition comprising black tea flavonoids as a prebiotic and/or for the treatment or prevention of conditions associated with poor gut health or low immunity. The flavonoids comprise thearubigin in an amount of at least 82% by weight of the tea flavonoids. Also provided is an edible product comprising the black tea flavonoids. | 11-25-2010 |
| 20100303752 | USE OF POLYMERIC GUANIDINES FOR CONTROLLING MICROORGANISMS - The invention relates to the use of polymeric guanidinium hydroxides based on a diamine which contains oxyalkylene chains and/or alkylene groups between two amino groups, obtainable by polycondensation of a guanidine acid addition salt with the diamine, whereby a polycondensation product in the form of a salt is obtained, which subsequently is converted into the hydroxide form via basic anion exchange, for controlling microorganisms. | 12-02-2010 |
| 20100303753 | Oligomer Conjugates of Lidocaine and Its Derivatives - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. | 12-02-2010 |
| 20100316590 | COMPOSITIONS AND METHODS RELATED TO POLOXAMER COPOLYMER MEMBRANE SEALANT - Embodiments of the invention include the treatment of amyloid oligomer toxicity by administering a membrane sealant co-polymer, for example poloxamer 188 (P188). | 12-16-2010 |
| 20100316591 | BIOABSORBABLE POLYMERS - Described herein are biocompatible compositions that contain a copolymer and a filler material. In particular, described herein are compositions that include a copolymer and a filler which may be a calcium salt. Also described herein are methods in which the compositions are used to attach soft tissue to bone. | 12-16-2010 |
| 20100322891 | Immuniostimulating polyphosphazene compounds - Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed. | 12-23-2010 |
| 20110002877 | PTEN Inhibitors Treat Neutropenia-Associated Pneumonia - Neutropenia-associated pneumonia is treated with a therapeutically effective amount of a small-molecule PTEN inhibitor. The method may further include detecting a resultant alleviation of the neutropenia-associated pneumonia, and/or diagnosing the neutropenia-associated pneumonia. The patient may be undergoing anti-cancer chemotherapy and/or radiotherapy, and the methods may further include the step of treating the patient with broad-spectrum antibiotic therapy or granulocyte colony-stimulating factor (G-CSF) therapy. | 01-06-2011 |
| 20110008277 | POLYOL-BASED POLYMERS - The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or maltitol) condensed with polycarboxylic acid units (e.g., citric acid, glutaric acid, or sebacic acid). The inventive polymers may be further derivatized or modified. For example, the polymer may be made photocrosslinkable by adding methacrylate moieties to the polymer. | 01-13-2011 |
| 20110020265 | USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS - Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis ( | 01-27-2011 |
| 20110044933 | PARTICLES, OBTAINED BY DRYING AN AQUEOUS NANOUREA DISPERSION - The present invention relates to particles produced by drying aqueous dispersions of nanoureas and to methods for the production thereof. | 02-24-2011 |
| 20110052524 | VERTEBROPLASTY METHOD USING AN ADDITION CURABLE POLYSILOXANE SYSTEM - The invention relates generally to treatments of disordered bony structures, in particular to vertebroplasty compositions and methods and, more specifically, to treating vertebral bodies in living creatures, in particular, human beings and also compositions suitable for use in such methods and preparation and use of such compositions. According to the invention the composition to be used is an addition curable polysiloxane system. | 03-03-2011 |
| 20110123479 | MEDICAL ADHESIVES FOR STOPPING HEAVY BLEEDING AND SEALING LEAKAGES - The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) | 05-26-2011 |
| 20110129436 | POLYGLYCEROL SEBECATE PERITONEAL ADHESION PREVENTION BARRIER - The present invention is directed to a method of preventing adhesions between two tissue surfaces. The method includes providing a film comprising a condensation polymer of glycerol and a diacid, wherein the film does not contain anti-inflammatory drugs and positioning the film between a first tissue surface and a second tissue surface under conditions effective to prevent adhesion between said first tissue surface and said second tissue surface. | 06-02-2011 |
| 20110129437 | PLATELET ADHESION-RESISTANT MATERIAL - A platelet adhesion-resistant material is provided, which includes polytriuret-urethane consisting essentially of repeating structural units of formulae (I) to (III) in a random order, in which when the total number of the three repeating structural units in the polytriuret-urethane is 100, the number of the repeating structural units (I) is about 5 to about 50: | 06-02-2011 |
| 20110142790 | Polyol Based - Bioceramic Composites - Polyol-bioceramic composites are prepared by the reaction of a polyol and polycarboxylic acid in the presence of a bioceramic. Implantable medical devices fabricated at least in part with the crosslinked polyol-bioceramic composite materials are useful in a wide variety of applications. | 06-16-2011 |
| 20110212050 | SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS - Inherently radiopaque side-chain crystallizable polymers (IRSCCP's) are useful in various medical applications. An example of a IRSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer, the heavy atoms being present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes a IRSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. | 09-01-2011 |
| 20110243885 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function - This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease. | 10-06-2011 |
| 20110268690 | POLYMERS CONTAINING POLY(HYDROXYALKANOATES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME - Compositions comprising poly(hydroxyalkanoates) and agents for use with medical articles are described. | 11-03-2011 |
| 20110274645 | Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods - Methods of performing medical procedures, and methods of making bone-growth-promoting compositions useful in performing medical procedures are provided. Apparatus useful both in methods of performing medical procedures, and in methods of making bone-growth-promoting compositions useful in performing medical procedures, are provided. The bone-growth-promoting compositions made according to the disclosed methods are biocompatible, and are adapted to stimulate bone growth when positioned in contact with, or in the vicinity of, a bone of a mammal. | 11-10-2011 |
| 20110286958 | HPMA POLYMER PLATINUM CHELATES - Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer. | 11-24-2011 |
| 20110286959 | Copolymers for suppression of autoimmune diseases, and methods of use - Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J (H-2 | 11-24-2011 |
| 20120014909 | TISSUE ADHESIVE AND SEALANT COMPRISING POLYGLYCEROL ALDEHYDE - A tissue adhesives and sealant formed by reacting a polyglycerol aldehyde with a water-dispersible, multi-arm amine is described. The tissue adhesive and sealant may be useful for medical and veterinary applications, including, but not limited to, wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions. | 01-19-2012 |
| 20120027718 | COMBINATION THERAPY WITH GLATIRAMER ACETATE AND RASAGILINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 02-02-2012 |
| 20120027719 | Polyester Based Degradable Materials and Implantable Biomedical Articles Formed Therefrom - A method of making an aliphatic polyester prepolymer, comprising: reacting, alone or in combination with other reactants, a diol with at least a first diacid (or a diester of said first diacid) to produce an aliphatic polyester prepolymer. The first diacid is preferably a trans-beta-hydromuconic acid (HMA). In some embodiments, the diol contains at least one ether linkage. In some embodiments the diol is further reacted with at a second diacid, or a diester of said second diacid, wherein said second diacid is different from said first diacid. Prepolymers produced from such processes and articles formed therefrom are also described. | 02-02-2012 |
| 20120064027 | Absorbable adhesive paste - An absorbable adhesive paste contains absorbable solid carboxy-bearing microparticles dispersed in a continuous phase of an alkoxyalkyl cyanoacrylate. The paste may contain a soluble absorbable polymeric viscosity modifier and at least one bioactive agent to maximize the effective application as a cover for compromised tissues and wounds or as sealants, blocking agents, or hemostatic agents. | 03-15-2012 |
| 20120082638 | Water-Soluble and Biodegradable Antimicrobial Agent - A water-soluble and biodegradable antimicrobial agent is provided, comprising a polymer composed of a segment A and a segment B, in which, the segment A has the following formula I: | 04-05-2012 |
| 20120121534 | INJECTABLE COMPOSITION COMBINING A FILLING AGENT AND A FIBROBLAST GROWTH MEDIUM - The invention relates to a composition that can be subcutaneously or intradermally injected, comprising: a filling agent; and a fibroblast growth medium. | 05-17-2012 |
| 20120134953 | ANTI-MICROBIAL COMPOSITION - Anti-microbial compositions including an anti-microbial polymer containing silicon-containing quaternary ammonium groups, polyvinyl alcohol (PVA), at least one short chain alcohol, optional fragrance, and water are provided. The anti-microbial compositions may be used to disinfect both porous and non-porous surfaces. Exemplary compositions may include 0.1-10 wt % of the anti-microbial polymer containing silicon-containing quaternary ammonium groups, 0.1-10 wt % polyvinyl alcohol (PVA), 1.0-20 wt % isopropyl alcohol, optional fragrance, and water. | 05-31-2012 |
| 20120171156 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES - Conventional commercial hair dyes form potent allergens and may also have irritant properties. If they were not already well established in the market and the side effects tolerated by consumers they would likely be deemed unsafe for use. The invention relates to compounds, compositions, formulations and methods for reducing, avoiding or eliminating allergic contact dermatitis reactions to conventional commercial hair dyes. | 07-05-2012 |
| 20120183494 | NOVEL N-HALAMINE ACRYLAMIDE MONOMERS AND COPOLYMERS THEREOF FOR BIOCIDAL COATINGS - Novel acrylamide and methacrylamide hydantoin monomers which can be reacted with other acrylamide, methacrylamide, acrylate, and methacrylate monomers to form copolymers, which upon halogenation, provide oxidative coatings which are biocidal for use with various materials including, but not limited to, textiles, filters, and latex paints. | 07-19-2012 |
| 20120195850 | USE OF POLYMER D-LACTIC ACID (PDLA) OR EQUIVALENTS THEREOF TO INHIBIT GROWTH OF CANCER CELLS AND DIAGNOSE CANCERS - The invention provides method for sequestering or trapping L-lactate in or near a tumor cell comprising contacting an isolated polymer of D-lactic acid (PDLA) or an equivalent, derivative or analog thereof with the tumor cell so that the PDLA binds L-lactate in or near the cell and thereby sequestering or trapping L-lactate in or near the tumor cells. | 08-02-2012 |
| 20120219521 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS - Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents. | 08-30-2012 |
| 20120225027 | TOXICITY ENHANCING COMPOUNDS AND METHODS - A method of treating a tumor or cancer in a subject includes administering to cancer or tumor cells of the subject a radiation sensitizing amount of a poly(ethylene oxide)-poly(propylene oxide) copolymer and administering radiation therapy to the cancer or tumor cells sensitized by the poly(ethylene oxide)-poly(propylene oxide) copolymer. | 09-06-2012 |
| 20120244106 | USE OF THE COMBINATION OF TERIFLUNOMIDE AND GLATIRAMER ACETATE FOR TREATING MULTIPLE SCLEROSIS - This invention is related to the use of the combination of teriflunomide or a pharmaceutically acceptable salt thereof and glatiramer acetate for treating multiple sclerosis. | 09-27-2012 |
| 20120244107 | BIODEGRADABLE HYDROGEL - The present invention relates to a hydrogel on the basis of polyurethane or polyurethane urea, said hydrogel comprising hydrolysable functional groups in the polymer chain, to a method for producing the hydrogel and to the use of the hydrogel as adhesion barriers. | 09-27-2012 |
| 20120269762 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION - The invention broadly relates to the use of the Active in the causal treatment of a disease caused by axonal demyelination, in which the Active maintains the integrity of myelination (for example by promoting remyelination, and/or preventing demyelination, of the axonal sheaths). The invention is particularly directed to the causal treatment of CNS demyelination diseases, for example MS, especially primary progressive MS and/or relapse remitting MS, and PNS demyelination diseases, for example Charcot-Marie-Tooth Disease. The Active of the invention may be suitably administered when a patient is in relapse (i.e. upon relapse), and be continued while the patient is in relapse, with a view to attenuating the severity of the relapse, and/or accelerating disease remission. Alternatively, the Active may be administered continuously with a view to prolonging the remission period, and/or attenuating the severity of the relapse, and/or preventing relapse. The invention also relates to the use of the Active as a treatment for symptoms of demyelination disease, especially MS, selected from vision deficits, motor control deficits, and sensation deficits. | 10-25-2012 |
| 20120294826 | METHODS, KITS AND COMPOSITIONS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS - The present invention provides, inter alia, methods for ameliorating an adverse effect in a patient caused by an acute transfusion into the patient of a composition containing aged red blood cells using an iron chelator. Apparatuses and kits for ameliorating such adverse effects are also provided. | 11-22-2012 |
| 20120294827 | POLYMER GEL FORMULATION - A polymer gel, in at least some embodiments, featuring both cross-linked castor oil and branched castor oil components, in which the castor oil is optionally replaced by ricinoleic acid. | 11-22-2012 |
| 20120308509 | Method and Composition for In Situ Formation of an Artificial Blockage to Control Blood Loss - Two siloxane-based mixtures combine to form a soft or semi-solid matrix for forming an artificial blockage to control bleeding, particularly moderate to severe bleeding. The first component includes a homogeneous mixture or solution that includes a polymeric matrix, a surfactant, filler(s) and metal compound(s). The second component includes a homogeneous mixture or solution that includes a polymer(s), a filler(s), a surfactant, and hydrogen peroxide. The combination of the two components is carried out with adequate mixing using mechanical and micro-kinetic mixing mechanisms and can be performed in a field-ready delivery device. | 12-06-2012 |
| 20120321586 | SURFACTANT COMPOSITION - The disclosure describes a composition comprising a lipidaceous carrier and a peptide complex formed from poly-L-lysine or a salt thereof; and either poly-L-glutamic acid or poly-L-aspartic acid, or a salt thereof. The composition can be used to prevent or treat a disease related to pulmonary surfactant dysfunction, such as hyaline membrane disease (HMD), respiratory distress syndrome (RDS), hydrocarbon poisoning, near-drowning, HIV/AIDS-related lung diseases, adult respiratory distress syndrome (ARDS), asthma, tuberculosis (TB) or severe acute respiratory syndrome (SARS). Alternatively, the composition can be used to increase the permeability of a pharmaceutical compound or composition across a membrane of a subject. The poly-L-lysine or salt thereof is longer than the poly-L-glutamic acid or poly-L-aspartic acid so that the complex that forms has a charge-neutralised region and a positively-charged region. The charge-neutralised region of the peptide complex interacts with the lipidaceous carrier, while the positively-charged region interacts with an aqueous and/or polar environment. | 12-20-2012 |
| 20130071349 | BIODEGRADABLE POLYMERS FOR LOWERING INTRAOCULAR PRESSURE - The present invention provides a method of treating glaucoma, the method comprising the step of placing a polymer in an eye of a patient, which biologically degrades over a period of time to release biodegradants, which are effective to lower the intraocular pressure of the patient, thereby treating glaucoma. Said polymer is preferably selected from the group consisting of polymers of lactic acid, glycolic acid and/or mixtures thereof. More preferably the polymer is a copolymer of lactic acid and glycolic acid, e.g. a copolymer comprising from 50 to 100% lactic acid and from 0 to 50% glycolic acid, by weight. | 03-21-2013 |
| 20130089512 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS - New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 04-11-2013 |
| 20130115186 | SILICON-CONTAINING BIODEGRADABLE MATERIAL FOR ANTI-INFLAMMATORY THERAPY - The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with increased interleukin-1β and/or interleukin-6 and/or interleukin-8 activity and/or that can be treated by lowering said cytokine activity. | 05-09-2013 |
| 20130115187 | BIODEGRADABLE MATERIAL CONTAINING SILICON, FOR PRO-ANGIOGENETIC THERAPY - The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with reduced and/or disturbed angiogenesis and/or diseases for which an increased rate of angiogenesis is beneficial to the healing process. | 05-09-2013 |
| 20130129666 | BIOMATERIAL CONTAINING DEGRADATION STABILIZED POLYMER - The invention provides a polymer based material comprising a water binding agent present in an amount sufficient to chemically and/or physically absorb and/or adsorb water to prevent degradation of the polymer. The invention also provides a polymer based material comprising a plasticizer or organic solvent as well as a multi-component material or composite including materials encompassing a second polymer and/or an active agent. The invention further provides a pharmaceutical composition comprising the aforesaid polymer based material, which can be used for treatment of bone, cartilage and/or periodontal defects. | 05-23-2013 |
| 20130156725 | RANDOM PENTAPOLYMER FOR TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to a synthetic polypeptide which is a random linear pentapolymer comprising alanine, glutamic acid, lysine, tyrosine and phenylalanine and use thereof in treating autoimmune diseases, in particular multiple sclerosis. | 06-20-2013 |
| 20130164250 | METHOD FOR PRODUCTION OF BIORESORBABLE MICROPARTICLES, MICROPARTICLES THUS OBTAINED AND USE THEREOF - Nonlamellar bioresorbable microparticles to which protein substances are bonded, and a method for preparing the microparticles, comprising: (i) preparing the microparticles from at least one bioresorbable polymer without stabilizer and without surfactant; and (ii) bonding the protein substances to the microparticles obtained in step (i) without surfactant. | 06-27-2013 |
| 20130171093 | HEALING POWDER AND METHOD OF USE THEREOF - A wound healing powder, comprising a sugar selected from the group consisting of one or more pharmaceutically acceptable monosaccharides and disaccharides, in an amount of at least 25% by weight of the powder mixture; and an absorbent agent which forms a bioabsorbable biocompatible matrix with wound secretions, comprising a polymer formed of one or more of saccharide or saccharide derivative monomers and lactic acid monomers, in an amount of at least 25% by weight of the powder mixture. | 07-04-2013 |
| 20130189221 | POLYSACCHARIDE-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - Method of forming tissue adhesives by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described. | 07-25-2013 |
| 20130209391 | FUNCTIONALIZED POLYMER COMPOSITIONS - The invention relates to functionalized polymers including homopolymers and copolymers and their uses in industrial applications and in agricultural applications. In particular, the homopolymers and copolymers may be, for example, used in polymer blends, used as nutritives and in feed compositions, and used in combination with a pharmaceutical or nutritive. | 08-15-2013 |
| 20130251667 | AMIDE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester. | 09-26-2013 |
| 20130272996 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 10-17-2013 |
| 20140050692 | POLYESTERS AND METHODS OF USE THEREOF - The invention provides polymers and methods for the treatment of pain and inflammation. | 02-20-2014 |
| 20140105849 | BIOACTIVE ANILINE COPOLYMERS - Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be for example (A): where for example R | 04-17-2014 |
| 20140105850 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 04-17-2014 |
| 20140120057 | POLYMERS AND METHODS THEREOF FOR WOUND HEALING - Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): | 05-01-2014 |
| 20140120058 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES - The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a method of delivering such prostaglandin drugs to a subject, to a sustained drug delivery system comprising the polymer-drug conjugates, to a method of preparing the polymer-drug conjugates, and to an implant comprising the polymer-drug conjugates. The polymer-drug conjugates may be useful for delivering prostaglandins and substituted prostaglandins for the treatment of glaucoma. | 05-01-2014 |
| 20140127154 | PREGNANCY HORMONE COMBINATION FOR TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis. | 05-08-2014 |
| 20140154204 | SILANE-CONTAINING MOISTURE-CURABLE TISSUE SEALANT - A tissue sealant that includes the reaction product of (a) a polyol; (b) a polyisocyanate; and (c) an alkoxy silane having the formula: (R | 06-05-2014 |
| 20140170106 | METHODS AND COMPOSITIONS SUITABLE FOR IMPROVED REATTACHMENT OF DETACHED CARTILAGE TO SUBCHONDRAL BONE - The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage. | 06-19-2014 |
| 20140186291 | Chemically Modified Dendrimers - Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis. | 07-03-2014 |
| 20140219951 | AMIDO-AMINE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions. | 08-07-2014 |
| 20140248233 | BIOCOMPATIBLE COMPOSITE MATERIALS - An injectable composite material comprising a fibrous material comprised of a fir biocompatible low melting point polyester dispersed in a host medium comprised of second biocompatible low melting point polyester. | 09-04-2014 |
| 20140255336 | POLYPHOSPHATE-FUNCTIONALIZED INORGANIC NANOPARTICLES AS HEMOSTATIC COMPOSITIONS AND METHODS OF USE - A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting. | 09-11-2014 |
| 20140271531 | In-Situ Forming Foam for Endoscopic Lung Volume Reduction - Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a lung at or near an alveolar duct targeted for reduction, occluding the airway and leading to tissue necrosis because the foam prevents oxygenation of the tissue surrounding the duct. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in-situ foam formation). In addition, the foam may form a seal, eliminating the source of air leaks. | 09-18-2014 |
| 20140271532 | COMBINATION THERAPY WITH GLATIRAMER ACETATE AND RASAGILINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 09-18-2014 |
| 20140301970 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS - Gel-forming block copolymers were prepared comprising i) a central hydrophilic block consisting essentially of a divalent poly(ethylene oxide) chain and ii) two peripheral monocarbonate or polycarbonate hydrophobic blocks. The hydrophobic blocks comprise one or more vitamin-bearing subunits. The vitamin-bearing subunits comprise a carbonate backbone portion and a side chain comprising a covalently bound form of a vitamin. The gel-forming block copolymers can be used to prepare various biodegradable and/or biocompatible hydrogel and organogel drug compositions, in particular antimicrobial and/or anti-tumor drug compositions. The hydrogel compositions can be suitable for depot injections. Synergistic enhancement of toxicity to microbes was observed with compositions comprising an antimicrobial cationic polymer and an antimicrobial compound. | 10-09-2014 |
| 20140301971 | Medical Device Comprising Boswellic Acid - A medical composition and devices made from the composition for the delivery of extracts obtained from | 10-09-2014 |
| 20140301972 | USE OF BIOCOMPATIBLE POLYMERS FOR THE PREPARATION OF A COMPOSITION OR A MEDICAL DEVICE - The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR′ group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R′ or —RNS03R′ in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R′ denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same. In addition, in certain cases, the use of said biocompatible polymers for pain treatment can impact on the actual curing of certain diseases. Significant improvements and even cures have been observed in relation to chronic and painful diseases that are associated with alterations in the extracellular matrix regardless of the origin thereof. | 10-09-2014 |
| 20140314706 | ADVANCED FUNCTIONAL BIOCOMPATIBLE POLYMER PUTTY USED AS A HEMOSTATIC AGENT FOR TREATING DAMAGED TISSUE AND CELLS - A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism. | 10-23-2014 |
| 20140314707 | Immunostimulating Polyphosphazene Compounds - Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed. | 10-23-2014 |
| 20140322158 | METHODS OF TREATING A SUBJECT AFFLICTED WITH AN AUTOIMMUNE DISEASE USING PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY IN MULTIPLE SCLEROSIS - A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10/IL-18 ratio and IL-10/IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo-/non-responder. | 10-30-2014 |
| 20140363392 | OSTEOINDUCTIVE COATINGS FOR DENTAL IMPLANTS - The present invention relates to an osteoinductive coating for use in dental implants, which can be obtained using a sol-gel process from methyltrimethoxysilane (MTMOS) as a silicon base precursor, ethyl tetraorthosilicate (TEOS) as a hydrophilic silicon precursor and at least one silicon precursor selected from glycidoxypropyltrimethoxysilane and aminopropyltrimethoxysilane. The invention also relates to the method for obtaining said coating and to the use thereof in dental implants. | 12-11-2014 |
| 20140363393 | Method and Composition for In Situ Formation and/or Expansion of a Polymer-Based Hemostatic Agent to Control Bleeding - A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component. | 12-11-2014 |
| 20140369954 | D, L-CYCLIC PEPTIDE NANOTUBE REINFORCING AGENTS - The disclosed subject matter can provide a nanotube-reinforced polymer composite material comprising a plurality of nanotubes, each nanotube being formed of a plurality of cyclic peptide molecules, disposed within a polymer matrix, such as a biodegradable polymer matrix. A cyclic polymer, such as a cyclic 8-mer, composed of amino acid residues of alternating absolute configurations (D/L, R/S), can self-assemble into nanotubes useful for preparation of the composite polymer material of the invention. For example, the cyclic peptide (QL)4, wherein the glutamine and leucine residues are of opposite absolute configuration, self-assembles into nanotubes, which when formed into a reinforced polymer composite including poly(caprolactone), provides a biocompatible material of greater tensile strength and Young's modulus compared to the poly(caprolactone) material alone. The nanotubes can be prepared by a vapor equilibration technique or by a solvent-nonsolvent precipitation technique. The materials of the invention can be used for implants, stents and the like as well as for synthetic ligaments, tendons, cartilage, and bone for use in the living tissue of a patient in need thereof. For example, a spinal fusion cage comprising a PDLLA polymer matrix with a plurality of nanotubes of the invention can exhibit enhanced stiffness. | 12-18-2014 |
| 20150010492 | Methods and Compositions for the Disruption of Biofilms - The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms. | 01-08-2015 |
| 20150017117 | Composition for In Vivo Vessel Repair - The present invention relates to a biocompatible polymer composition, suitable for in vivo vessel repair, comprising a matrix pre-polymer, a filler and a curing agent, wherein said composition wherein said biocompatible polymer composition is curable in the presence of a curing catalyst at 37° C. to form a cured material with an elongation until rupture of at least 5% and an elastic modulus of at least 1 MPa. | 01-15-2015 |
| 20150030560 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS - The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal. | 01-29-2015 |
| 20150086504 | POLYMERIC MICROEMULSIONS - The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C. | 03-26-2015 |
| 20150093353 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL). | 04-02-2015 |
| 20150110733 | GENETIC MARKERS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE - The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:
| 04-23-2015 |
| 20150132251 | Biodegradable Elastomeric Patch for Treating Cardiac or Cardiovascular Conditions - Provided herein is a biodegradable elastomeric patch that can be implanted on a heart or other portions of the cardiovascular system to repair tissue deficiencies or tissue damage. The biodegradable elastomeric patch may be engineered to have mechanical properties similar to that of soft tissue and to provide mechanical support to the damaged tissue. The biodegradable elastomeric patch also may comprise therapeutic agents to aid in the healing process. Methods also are provided for using a biodegradable elastomeric patch for treating patients suffering from tissue damage or tissue deficiencies in the cardiac or cardiovascular system. | 05-14-2015 |
| 20150139935 | SLEEP APNEA TREATMENT - Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate. | 05-21-2015 |
| 20150366899 | Methods and Compositions for the Disruption of Biofilms - The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms. | 12-24-2015 |
| 20160000775 | USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS - Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, methods for treating a human subject by providing neuroprotection to the human subject, and methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, comprising orally administering to the human patient or subject a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, for use in treating a human subject by providing neuroprotection to the human subject, or for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient. | 01-07-2016 |
| 20160008381 | Combined Treatment Utilizing VB-201 | 01-14-2016 |
| 20160038532 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Glatiramer Acetate - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 02-11-2016 |
| 20160040236 | SYSTEMS AND METHODS FOR CHARACTERIZATION OF MULTIPLE SCLEROSIS - Methods and systems to characterize multiple sclerosis in a subject, e.g., in a subject a progressive form of MS are disclosed. | 02-11-2016 |
| 20160054320 | Markers for Determination of Patient Responsiveness - Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual's responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc. | 02-25-2016 |
| 20160060454 | FUNCTIONALIZED POLYMER COMPOSITIONS - The invention relates to functionalized polymers including homopolymers and copolymers and their uses in industrial applications and in agricultural applications. In particular, the homopolymers and copolymers may be, for example, used in polymer blends, used as nutritives and in feed compositions, and used in combination with a pharmaceutical or nutritive. | 03-03-2016 |
| 20160106833 | Immunostimulating Polyphosphazene Compounds - Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed. | 04-21-2016 |
| 20160158274 | COMPOSITION FOR MUCOUS DISPERSION OR HYDRATION, CONTAINING POLY-r-GLUTAMIC ACID - The present invention relates to a composition for dispersing or hydrating mucus, which comprises poly-gamma-glutamic acid, a biocompatible natural polymer, and more particularly, to a composition for treating mucus hypersecretory disease, which comprises poly-gamma-glutamic acid or poly-gamma-glutamic acid nanogels. The composition according to the present invention is effective in treating mucus-related diseases by effectively dispersing and hydrating mucus which is excessively secreted in vivo and highly sticky. | 06-09-2016 |
| 20160166603 | AGENT AND METHOD FOR TREATING HERPES | 06-16-2016 |
| 20160175343 | POLYMERS AND METHODS THEREOF FOR WOUND HEALING | 06-23-2016 |
| 20160184190 | FORMULATIONS AND MATERIALS WITH CATIONIC POLYMERS - This invention provides fluid formulations and materials produced therefrom for repairing dental and bone defects, processes for the production of the fluid formulations and materials, and to uses of these formulations and materials. In particular, the invention provides the use cationic polymers such as polylysine in these formulations and materials, and the advantageous properties derived therefrom which include mechanical and antibacterial properties. | 06-30-2016 |
| 20160184347 | MEDICINE FOR PREVENTING OR SUPPRESSING ENGRAFTMENT OF CANCER CELLS INCLUDING AN ORGANIC ACID POLYMER AS ACTIVE INGREDIENT - Pharmaceutical uses of an organic acid polymer, specifically a 3-oxygermylpropionic acid polymer. | 06-30-2016 |
| 20160194714 | BIOMARKERS FOR PREDICTING RELAPSE IN MULTIPLE SCLEROSIS | 07-07-2016 |
| 20160250172 | Neuroprotection in Demyelinating Diseases | 09-01-2016 |
| 20160250251 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY | 09-01-2016 |
| 20160250374 | Absorbable Multi-Putty Bone Cements and Hemostatic Compositions and Methods of Use | 09-01-2016 |
| 20160374335 | ANTIMICROBIAL POLYMERS FORMED BY BULK POLYADDITION - Cationic antimicrobial polymers have been synthesized by a bulk addition polymerization of a nucleophilic agent comprising two tertiary amines and an electrophilic agent that comprises two leaving groups and an aromatic ring between the leaving groups. The reaction solvent for the polymerization is chosen to allow precipitation of the cationic polymer at the polymerization temperature, thereby limiting molecular weight. Quaternization and polymerization occur concurrently. The cationic polymers can be highly active against Gram-negative and Gram-positive microbes, and/or fungi. The cationic polymers can also be non-hemolytic and non-cytotoxic at the effective concentration against the microbes. | 12-29-2016 |
| 20180021288 | Neuroprotection in Demyelinating Diseases | 01-25-2018 |
